This site is intended for healthcare professionals
News

MHRA (UK) approves Tukysa for the treatment of advanced HER2-positive breast cancer.- Seagen

Read time: 1 mins
Published:24th Feb 2021
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Tukysa (tucatinib + trastuzumab + capecitabine), from Seagen, for the treatment of advanced HER2-positive breast cancer. It has authorised the Tukysa combination for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have previously been treated with at least two prior anti-HER2 treatment regimens. Approval is based on results from the HER2CLIMB trial, that enrolled 612 patients with HER2-positive unresectable locally advanced or metastatic breast cancer who had previously received – separately or in combination – trastuzumab, pertuzumab and ado-trastuzumab emtansine (T-DM1).
Condition: Breast Cancer HER2+
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.